Definium Therapeutics is trading 4.1% down at $43.80 as shares pull back following a sharp rally driven by positive Phase 3 Emerge trial results for DT120 ODT in major depressive disorder.
- The recent surge was also supported by a $700 million equity raise priced at $34 per share.
- With no fresh company news today, the move reflects profit-taking and consolidation following the recent jump, amid a weaker biotech tape.